BRIEF-Ionis Pharma Says Roche Has Exercised Option To License IONIS-HTT(Rx)
Dec 11 (Reuters) - Ionis Pharmaceuticals Inc:
* IONIS PHARMACEUTICALS LICENSES IONIS-HTT RX TO PARTNER FOLLOWING SUCCESSFUL PHASE 1/2A STUDY IN PATIENTS WITH HUNTINGTON‘S DISEASE
* IONIS PHARMA SAYS ROCHE HAS EXERCISED OPTION TO LICENSE IONIS-HTT(RX)
* IONIS PHARMACEUTICALS INC - ROCHE WILL NOW BE RESPONSIBLE FOR ALL DEVELOPMENT AND COMMERCIAL ACTIVITIES FOR IONIS-HTT(RX)
* IONIS PHARMACEUTICALS INC - IN CONJUNCTION WITH DECISION TO LICENSE IONIS-HTT(RX), IONIS EARNED A $45 MILLION LICENSE FEE FROM ROCHE. Source text for Eikon: Further company coverage: